| Expression pattern: |
UP |
| Associated gene: |
PSIP1, c-Myc |
| Associated microRNA: |
- |
| Biological function: |
promotes HCC progression, enhances tumor stemness, and contributes to lenvatinib resistance; promotes proliferation, colony formation, invasion, migration; reduces apoptosis |
| Molecular mechanism: |
circRNA-mTOR binds PSIP1 and promotes its nuclear translocation, increasing nuclear c-Myc retention/stability via reduced ubiquitination, thereby enhancing stemness and lenvatinib resistance |
| Biological pathway or process: |
stemness (promotes); proliferation (promotes); invasion (promotes); migration (promotes); apoptosis (inhibits); drug resistance (promotes); ubiquitination (inhibits) |
| Detected method: |
Q
M
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; Clinical Sample Validation; Cohort Study; Survival Analysis; ROC Analysis; RNA Pull-Down; RIP (RNA Immunoprecipitation); IF (Immunofluorescence); Transfection; CCK8; Colony Formation Assay; Transwell Assay; Wound Healing Assay; Annexin V/PI Flow Cytometry; Western Blot; Co-IP; In Vivo Animal Model; IHC (Immunohistochemistry); Bioinformatics Analysis; Microarray |
| Clinical significance: |
High circRNA-mTOR expression shows good diagnostic power and is associated with worse RFS and OS in HCC patients |
| Description: |
circRNA-mTOR is upregulated in HCC and promotes tumor progression and lenvatinib resistance by enhancing stemness. Mechanistically, it binds PSIP1 to increase PSIP1 nuclear translocation, which increases nuclear c-Myc retention/stability (reduced ubiquitination), activating the PSIP1/c-Myc axis. |
| Confidence score: |
0.8999 |